10:01 AM EST, 12/13/2024 (MT Newswires) -- Eli Lilly's ( LLY ) Mounjaro will not receive a recommendation from the European Medicines Agency for a separate indication for the treatment of obstructive sleep apnea, the regulator said Friday.

The EMA said a separate label isn't needed as the use of Mounjaro is already covered by the approved indication for weight management.

The regulator noted that based on studies, its human medicines committee acknowledged that the drug improves obstructive sleep apnea in adults with obesity.

The EMA also said it agreed that data the company filed on sleep apnea can be included in the drug's product information to ensure that health care professionals have access to data on Mounjaro's effects.

Eli Lilly ( LLY ) didn't immediately respond to a request for comment from MT Newswires.

The company's shares were up 0.8% in recent Friday trading.

Price: 790.40, Change: +8.04, Percent Change: +1.03